Question 1
How do LAIs compare to oral medications in terms of adherence?
Question 2
Why is continuous dialogue important when using LAIs?
Question 3
What is one key benefit of Long-Acting Injectable Antipsychotics (LAIs) in patients with schizophrenia?
Question 4
Why is early intervention with LAIs important in patients newly diagnosed with schizophrenia?
Question 5
What is a practical approach to convincing patients to try LAIs?
Question 6
What are the irreversible effects of non-adherence in schizophrenia patients?
Question 7
What should be the focus of conversations around Long-Acting Injectable Antipsychotics (LAIs) with patients?
Question 8
What is an essential part of optimizing outcomes with LAIs?
Question 9
Which chronic conditions show adherence rates similar to those observed in patients with schizophrenia taking oral medications?
Question 10
In the context of LAIs, what factor is crucial in determining the frequency and type of injection for a patient?
Question 11
What is a primary reason many people with chronic illnesses, including schizophrenia, are non-adherent with their medications?
Question 12
What is the role of LAIs in comparative effectiveness for symptom reduction?
Question 13
What percentage of patients with schizophrenia are partially or non-adherent to their medication regimen?
Question 14
What is emphasized as the most effective tool in modern psychiatry concerning medication?
Question 15
How often can Long-Acting Injectable Antipsychotics (LAIs) be administered?